Incyte Corp., of Wilmington, Del., said it earned a $25 million milestone from Novartis AG, of Basel, Switzerland, triggered by the EMA's positive opinion of Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea.